Roberto Mina, MD, associate professor of hematology at the Winship Cancer Institute at Emory University, highlighted the pivotal role of B-cell maturation antigen (BCMA) targeting therapies. Key Differences in Clinical Trial DesignThe primary distinction between the MajesTEC-3 (NCT05083169) and MajesTEC-9 (NCT05572515) trials lies in the therapeutic combinations utilized. Beyond the drug combinations, the trials vary based on the prior treatment history of the enrolled patients. Both trials enrolled patients with 1 to 3 prior lines of therapy, thus including patients after their first relapse. Ultimately, the existence of multiple BCMA-targeting platforms—bispecific antibodies, CAR T-cells, and ADCs—provides clinicians with a complementary toolkit.